Compare SYM & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYM | RYTM |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.4B |
| IPO Year | 2021 | 2017 |
| Metric | SYM | RYTM |
|---|---|---|
| Price | $55.15 | $103.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $54.23 | ★ $129.92 |
| AVG Volume (30 Days) | ★ 2.2M | 586.8K |
| Earning Date | 05-06-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,246,922,000.00 | N/A |
| Revenue This Year | $24.66 | $47.98 |
| Revenue Next Year | $27.88 | $56.07 |
| P/E Ratio | $2,707.00 | ★ N/A |
| Revenue Growth | ★ 25.65 | N/A |
| 52 Week Low | $16.32 | $45.91 |
| 52 Week High | $87.88 | $122.20 |
| Indicator | SYM | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 48.88 |
| Support Level | $53.06 | $95.44 |
| Resistance Level | $64.41 | $104.50 |
| Average True Range (ATR) | 4.18 | 5.48 |
| MACD | -0.10 | -0.18 |
| Stochastic Oscillator | 31.46 | 46.27 |
Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.